论文部分内容阅读
目的:探讨扶正固本方加减联合放化疗对脑额叶胶质瘤患者术后预后的影响。方法:随机数字表格法将88例脑额叶胶质瘤患者分为观察组与对照组,各44例,对照组术后给予放化疗干预,观察组在对照组基础上加以扶正固本方加减治疗,比较两组近期疗效、不良反应、治疗前后KPS评分及T淋巴细胞亚群指标。同时随访6~12个月,统计两组生存率。结果:观察组近期总有效率88.64%显著高于对照组的70.45%(P<0.05);观察组骨髓抑制、恶心呕吐发生率显著低于对照组(P<0.05);与治疗前比较,观察组治疗后KPS评分、CD4+、CD4+/CD8+均显著上升(P<0.05),且与对照组比较差异有统计学意义(P<0.05)。观察组随访6个月、12个月生存率分别为100.00%、84.09%显著高于对照组的90.91%、61.36%,差异有统计学意义(P<0.05)。结论:扶正固本方加减联合放化疗治疗脑额叶胶质瘤安全有效,能明显增强患者机体免疫功能,显著提高其1年生存率。
Objective: To investigate the effect of Fuzheng Guben decoction combined with radiotherapy and chemotherapy on prognosis of patients with frontal lobe glioma. Methods: Eighty-eight patients with brain-frontal gliomas were divided into observation group and control group by random number table method, 44 cases in each group. The control group received radiotherapy and chemotherapy after operation. The observation group was given Fuzheng Guben Plus After treatment, the short-term curative effect, adverse reaction, KPS score and T lymphocyte subsets before and after treatment were compared. At the same time follow-up 6 to 12 months, the survival rate of two groups were calculated. Results: The total effective rate in the observation group was 88.64%, which was significantly higher than that in the control group (70.45%, P <0.05). The incidence of bone marrow suppression and nausea and vomiting in the observation group was significantly lower than that of the control group (P <0.05) The KPS score, CD4 +, CD4 + / CD8 + were significantly increased after treatment (P <0.05), and the difference was statistically significant compared with the control group (P <0.05). The observation group was followed up for 6 months. The 12-month survival rates were 100.00% and 84.09% respectively, which were significantly higher than those in the control group (90.91% and 61.36%, P <0.05). Conclusion: Fuzheng Guben Decoction combined with chemoradiotherapy for the treatment of frontal lobe glioma is safe and effective, can significantly enhance the immune function of patients, significantly improve their 1-year survival rate.